In a trial of patients with T2DM and BMI 27 kg/m2 or more receiving semaglutide injection for weight management, retinal disorders were reported by 6.9% of patients treated with semaglutide 2.4 mg/week, 6.2% of patients treated with semaglutide 1 mg/week, and 4.2% of patients treated with placebo
Two patients at day 7 may differ substantially: one may have persistent hypoperfusion and BBB leakage, whereas another may be entering immune resolution and angiogenesis
doi: 10.1371/journal.pone.0186802 386 MissailidisDAnnesleySJAllanCYSanislavOLidburyBALewisDPet al
These studies suggest that the peptide is well-tolerated, with no known toxic limitbut we dont yet know if the same results would occur in humans
Studies frequently explore cellular signaling, actin and cytoskeletal organization, angiogenic markers, and stress-response pathways